A global challenge with a simple solution

Our proprietary insulin independent solution can help type 2 diabetes (T2D) patients back to a healthy life. T2D patients don’t need to be restricted by their diagnosis. With the Atrogi solution, they can once again lead healthy lives.

  • Insulin independent – to give you the conditions needed to lead a healthy life
  • Your choice – you need to want it, the treatment will help you but your choices are key

  • Normal – Sugar levels back to normal with our revolutionary treatment

Our approach

The challenge

1 in 11 people are diagnosed with diabetes. The treatments available today are based on old discoveries leaving many patients short of accepted treatment goals. We have a solution for this with our innovative, insulin independent oral solution.

The challenge

Our solution

We have discovered an unprecedented insulin independent approach to treat T2D. This will allow for a unique mode of action separating desired effect from side effects. This means minimal side effects for the patients, and a healthier life!

Our solution
0 million
people diagnosed with T2D
0 million
deaths attributes to T2D
of diabetics have T2D
0 billion USD
spent on diabetes,that’s 12% of global health expenditure

Diabetes is a growing global epidemic. We need a solution which is simple, reliable and safe.
Atrogi is developing an insulin independent treatment to help T2D patients have a healthy life again!

Latest news

5MSEK fund granted

SWElife grant Atrogi awarded 5 MSEK Atrogi was awarded a 5 MSEK grant. This very prestigeful grant from the SWElifes accelerator program was received in [...]

“With 20 years of research behind me I can say the one constant throughout the years has been curiosity. My drive and passion for solving compartmental problems that fit into a whole and ultimately be administered into a human have always been fueled by my enormous curiosity.”

Tore Bengtsson, Founder and Chief Scientific Officer

Strategic Partners

Discover The Future

We are a multi-disciplinary team committed to focused and efficient drug development

Contact Us